These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 6442059)

  • 21. Should one use second-line agents such as gold and D-penicillamine in a patient with active rheumatoid arthritis and asymptomatic microscopic haematuria for which no cause can be determined?
    Bird HA
    Br J Rheumatol; 1989 Feb; 28(1):39. PubMed ID: 2492869
    [No Abstract]   [Full Text] [Related]  

  • 22. [HLA system and complications of the treatment of rheumatoid polyarthritis with D-penicillamine].
    Bardin T; Dryll A; Ryckewaert A
    Rev Rhum Mal Osteoartic; 1986 Jan; 53(1):27-9. PubMed ID: 3486448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between D-penicillamine--induced proteinuria and prior gold nephropathy.
    Billingsley LM; Stevens MB
    Johns Hopkins Med J; 1981 Feb; 148(2):64-7. PubMed ID: 7206401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Myasthenia induced by D-penicillamine. Apropos of 2 case reports].
    Huaux JP; Delreux V
    Acta Neurol Belg; 1986; 86(5):297-303. PubMed ID: 3492852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trial comparing D-penicillamine and gold in rheumatoid arthritis. Preliminary report.
    Huskisson EC; Gibson TJ; Balme HW; Berry H; Burry HC; Grahame R; Hart FD; Henderson DR; Wojtulewski JA
    Ann Rheum Dis; 1974 Nov; 33(6):532-5. PubMed ID: 4216306
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug-induced IgA deficiency in rheumatoid arthritis.
    Stanworth DR; Williamson JP; Shadforth M; Felix-Davies D; Thompson R
    Lancet; 1977 May; 1(8019):1001-2. PubMed ID: 67433
    [No Abstract]   [Full Text] [Related]  

  • 27. Auranofin in rheumatoid arthritis: use in patients with side-effects or lack of effect to gold sodium thiomalate or gold thioglucose and/or D-penicillamine. A prospective one year investigation.
    Manthorpe R; Tvede N; Bendixen G
    Scand J Rheumatol; 1988; 17(5):401-5. PubMed ID: 3145556
    [No Abstract]   [Full Text] [Related]  

  • 28. [Long-term comparative studies on gold, D-penicillamine, and NSAIDs for the treatment of early rheumatoid arthritis. 1. Evaluation of one year's treatment].
    Azuma T; Sugawara S; Maeda A; Miyauchi T; Aritomi H
    Ryumachi; 1986 Jun; 26(3):200-9. PubMed ID: 3097838
    [No Abstract]   [Full Text] [Related]  

  • 29. HLA system and side effects of gold salts and D-penicillamine treatment of rheumatoid arthritis.
    Bardin T; Dryll A; Debeyre N; Ryckewaert A; Legrand L; Marcelli A; Dausset J
    Ann Rheum Dis; 1982 Dec; 41(6):599-601. PubMed ID: 6959574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Early recognition of adverse effects, especially of kidney lesions, in patients with progressive chronic polyarthritis under D-Penicillamine therapy].
    Otto W; Pietruschka WD; Beenken O
    Z Gesamte Inn Med; 1975 Aug; 30(15):507-9. PubMed ID: 1189496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experiences with D-penicillamine with chronic polyarthritis].
    Mathies H; Schötz H; Schuh M
    Med Klin; 1970 Oct; 65(44):1929-33. PubMed ID: 5480422
    [No Abstract]   [Full Text] [Related]  

  • 32. [HLA DR7 as a protective factor against gold salt toxicity in rheumatoid arthritis].
    Rodríguez Pérez M; González Domínguez J; Matarán Pérez L; Salvatierra Ríos D
    An Med Interna; 1993 Oct; 10(10):484-6. PubMed ID: 8136425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies of rheumatoid arthritis among a tribe of Northwest Indians.
    Willkens RF; Blandau RL; Aoyama DT; Beasley RP
    J Rheumatol; 1976 Mar; 3(1):9-14. PubMed ID: 818380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis.
    Kean WF; Lock CJ; Howard-Lock HE; Buchanan WW
    Arthritis Rheum; 1982 Aug; 25(8):917-22. PubMed ID: 6214261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone.
    Grindulis KA; McConkey B
    Ann Rheum Dis; 1984 Jun; 43(3):398-401. PubMed ID: 6146295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-induced autoimmune disease.
    Spears CJ; Batchelor JR
    Adv Nephrol Necker Hosp; 1987; 16():219-29. PubMed ID: 3101425
    [No Abstract]   [Full Text] [Related]  

  • 37. HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment.
    Bliddal H; Eiberg B; Helin P; Svejgaard A
    Ann Rheum Dis; 1989 Jul; 48(7):539-41. PubMed ID: 2570550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetylator phenotypes in rheumatoid arthritis patients with or without adverse drug reactions to sodium-aurothiomalate or d-penicillamine.
    Rantapää Dahlqvist S; Mjörndal T
    Scand J Rheumatol; 1987; 16(4):235-9. PubMed ID: 3114874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Panmyelophthisis induced by the treatment of primary-chronic polyarthritis with gold and D-penicillamine].
    Baier H
    Schweiz Med Wochenschr; 1973 Dec; 103(51):1849-52. PubMed ID: 4587169
    [No Abstract]   [Full Text] [Related]  

  • 40. HLA-D antigens in rheumatoid arthritis and toxicity to gold and penicillamine.
    Nuotio P; Nissilä M; Ilonen J
    Scand J Rheumatol; 1986; 15(3):255-8. PubMed ID: 3492038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.